ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO1064

Incidence of CKD Stages 1-5 in Iceland

Session Information

Category: CKD (Non-Dialysis)

  • 1901 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention

Authors

  • Jonsson, Arnar Jan, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
  • Lund, Sigrun Helga, University of Iceland, Reykjavík, Iceland
  • Palsson, Runolfur, Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
  • Indridason, Olafur S., Landspitali - The National University Hospital of Iceland, Reykjavik, Iceland
Background

Chronic kidney disease (CKD) is a major public health problem with a prevalence in the range of 5-10%, but its incidence is less clear due to lack of longitudinal data. The aim of this study was to estimate the incidence of CKD stages 1-5 based on serum creatinine (SCr) measurements, albuminuria and other markers of kidney damage.

Methods

In this retrospective study from 2008 to 2016, we obtained all standardized SCr and urine protein measurements from every clinical laboratory in Iceland. Information on age, sex, kidney-specific diagnoses and co-morbid conditions were also retrieved from nationwide electronic medical records. eGFR was calculated from SCr using the CKD-EPI equation. Incidence of CKD was defined as presence of kidney damage or eGFR <60 mL/min/1.73m2 for more than 3 months, in individuals without CKD at study entry. Kidney damage was defined as albuminuria or presence of kidney-specific diagnoses including glomerular diseases and structural kidney abnormalities. CKD was staged according to the KDOQI guidelines. Incidence rates were standardized to the EU27 population.

Results

We obtained 2,049,482 SCr values for 213,011 individuals. The median (range) age was 63 (18–109) years; 47% were men. A total of 205,484 did not have evidence of CKD upon study entry, of whom 21,160 developed CKD during the study period. The annual age-standardized incidence of CKD 1–5 per 100,000 was 1,023 in men and 1,323 in women. The annual age-standardized incidence of CKD per 100,000 in men was 117 for stage 1, 153 for stage 2, 514 for stage 3A, 184 for stage 3B, 58 for stage 4 and 16 for stage 5 CKD. In women, the age-standardized incidence of CKD per 100,000 was 198 for stage 1, 141 for stage 2, 678 for stage 3A, 247 for stage 3B, 63 for stage 4 and 12 for stage 5 CKD.

Conclusion

This nationwide Icelandic study comprising SCr values and other markers of kidney damage from the majority of the Icelandic population indicates a CKD incidence of approximately 1% per year, although slightly higher in women than men.

Funding

  • Government Support - Non-U.S.